173 related articles for article (PubMed ID: 38618956)
41. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
[TBL] [Abstract][Full Text] [Related]
42. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.
Rohan SM; Xiao Y; Liang Y; Dudas ME; Al-Ahmadie HA; Fine SW; Gopalan A; Reuter VE; Rosenblum MK; Russo P; Tickoo SK
Mod Pathol; 2011 Sep; 24(9):1207-20. PubMed ID: 21602815
[TBL] [Abstract][Full Text] [Related]
43. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
[TBL] [Abstract][Full Text] [Related]
44. A Hypoxia-Inducible HIF1-GAL3ST1-Sulfatide Axis Enhances ccRCC Immune Evasion via Increased Tumor Cell-Platelet Binding.
Robinson CM; Poon BPK; Kano Y; Pluthero FG; Kahr WHA; Ohh M
Mol Cancer Res; 2019 Nov; 17(11):2306-2317. PubMed ID: 31427440
[TBL] [Abstract][Full Text] [Related]
45. High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma.
Wolff NC; Pavía-Jiménez A; Tcheuyap VT; Alexander S; Vishwanath M; Christie A; Xie XJ; Williams NS; Kapur P; Posner B; McKay RM; Brugarolas J
Oncotarget; 2015 Jul; 6(19):16951-62. PubMed ID: 26219258
[TBL] [Abstract][Full Text] [Related]
46. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
[TBL] [Abstract][Full Text] [Related]
47. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
[TBL] [Abstract][Full Text] [Related]
48. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
49. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.
Esteban MA; Tran MG; Harten SK; Hill P; Castellanos MC; Chandra A; Raval R; O'brien TS; Maxwell PH
Cancer Res; 2006 Apr; 66(7):3567-75. PubMed ID: 16585181
[TBL] [Abstract][Full Text] [Related]
50. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
51. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.
Beroukhim R; Brunet JP; Di Napoli A; Mertz KD; Seeley A; Pires MM; Linhart D; Worrell RA; Moch H; Rubin MA; Sellers WR; Meyerson M; Linehan WM; Kaelin WG; Signoretti S
Cancer Res; 2009 Jun; 69(11):4674-81. PubMed ID: 19470766
[TBL] [Abstract][Full Text] [Related]
52. CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma.
Schokrpur S; Hu J; Moughon DL; Liu P; Lin LC; Hermann K; Mangul S; Guan W; Pellegrini M; Xu H; Wu L
Sci Rep; 2016 Jun; 6():29032. PubMed ID: 27358011
[TBL] [Abstract][Full Text] [Related]
53. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
54. VHL gene alterations in Italian patients with isolated renal cell carcinomas.
Muscarella LA; D'Agruma L; la Torre A; Gigante M; Coco M; Parrella P; Battaglia M; Carrieri G; Carella M; Zelante L; Fazio VM; Gesualdo L; Ranieri E
Int J Biol Markers; 2013 Jun; 28(2):208-15. PubMed ID: 23558940
[TBL] [Abstract][Full Text] [Related]
55. Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma.
Hu J; Tan P; Ishihara M; Bayley NA; Schokrpur S; Reynoso JG; Zhang Y; Lim RJ; Dumitras C; Yang L; Dubinett SM; Jat PS; Van Snick J; Huang J; Chin AI; Prins RM; Graeber TG; Xu H; Wu L
Signal Transduct Target Ther; 2023 Apr; 8(1):155. PubMed ID: 37069149
[TBL] [Abstract][Full Text] [Related]
56. Simultaneous targeted activation of Notch1 and Vhl-disruption in the kidney proximal epithelial tubular cells in mice.
Johansson E; Rönö B; Johansson M; Lindgren D; Möller C; Axelson H; Smith EM
Sci Rep; 2016 Aug; 6():30739. PubMed ID: 27491826
[TBL] [Abstract][Full Text] [Related]
57. VHL, the story of a tumour suppressor gene.
Gossage L; Eisen T; Maher ER
Nat Rev Cancer; 2015 Jan; 15(1):55-64. PubMed ID: 25533676
[TBL] [Abstract][Full Text] [Related]
58. Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells.
Wolf C; Smith S; van Wijk SJL
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408930
[TBL] [Abstract][Full Text] [Related]
59. Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells.
Harten SK; Esteban MA; Shukla D; Ashcroft M; Maxwell PH
Mol Cancer; 2011 Jul; 10():89. PubMed ID: 21791076
[TBL] [Abstract][Full Text] [Related]
60. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.
Nargund AM; Pham CG; Dong Y; Wang PI; Osmangeyoglu HU; Xie Y; Aras O; Han S; Oyama T; Takeda S; Ray CE; Dong Z; Berge M; Hakimi AA; Monette S; Lekaye CL; Koutcher JA; Leslie CS; Creighton CJ; Weinhold N; Lee W; Tickoo SK; Wang Z; Cheng EH; Hsieh JJ
Cell Rep; 2017 Mar; 18(12):2893-2906. PubMed ID: 28329682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
